{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T18:40:10Z","timestamp":1762540810148,"version":"3.37.3"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Altered glutamate signaling is thought to be involved in a myriad of psychiatric disorders. Positron emission tomography (PET) imaging with [<jats:sup>18<\/jats:sup>F]FPEB allows assessing dynamic changes in metabotropic glutamate receptor 5 (mGluR5) availability underlying neuropathological conditions. The influence of endogenous glutamatergic levels into receptor binding has not been well established yet. The purpose of this study was to explore the [<jats:sup>18<\/jats:sup>F]FPEB binding regarding to physiological fluctuations or acute changes of glutamate synaptic concentrations by a translational approach; a PET\/MRS imaging study in 12 healthy human volunteers combined to a PET imaging after an N-acetylcysteine (NAc) pharmacological challenge in rodents. No significant differences were observed with small-animal PET in the test and retest conditions on the one hand and the NAc condition on the other hand for any regions. To test for an interaction of mGuR5 density and glutamatergic concentrations in healthy subjects, we correlated the [<jats:sup>18<\/jats:sup>F]FPEB BP<jats:sub>ND<\/jats:sub> with Glu\/Cr, Gln\/Cr, Glx\/Cr ratios in the anterior cingulate cortex VOI; respectively, no significance correlation has been revealed (Glu\/Cr: <jats:italic>r<\/jats:italic>\u2009=\u20090.51, <jats:italic>p<\/jats:italic>\u2009=\u20090.09; Gln\/Cr: <jats:italic>r<\/jats:italic>\u2009=\u2009\u22120.46, <jats:italic>p<\/jats:italic>\u2009=\u20090.13; Glx\/Cr: <jats:italic>r<\/jats:italic>\u2009=\u2009\u22120.035, <jats:italic>p<\/jats:italic>\u2009=\u20090.92).These data suggest that the in vivo binding of [<jats:sup>18<\/jats:sup>F]FPEB to an allosteric site of the mGluR5 is not modulated by endogenous glutamate in vivo. Thus, [<jats:sup>18<\/jats:sup>F]FPEB appears unable to measure acute fluctuations in endogenous levels of glutamate.<\/jats:p>","DOI":"10.1038\/s41398-020-01152-2","type":"journal-article","created":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T12:03:28Z","timestamp":1611144208000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Study of influence of the glutamatergic concentration of [18F]FPEB binding to metabotropic glutamate receptor subtype 5 with N-acetylcysteine challenge in rats and SRM\/PET study in human healthy volunteers"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5095-9805","authenticated-orcid":false,"given":"Anne-Claire","family":"Dupont","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Serri\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5119-658X","authenticated-orcid":false,"given":"Laurent","family":"Barantin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7474-7778","authenticated-orcid":false,"given":"Johnny","family":"Vercouillie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clovis","family":"Tauber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0091-8159","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Gissot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Bodard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabrielle","family":"Chicheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1865-8380","authenticated-orcid":false,"given":"Sylvie","family":"Chalon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pr Fr\u00e9d\u00e9rique","family":"Bonnet-Brilhault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pr Maria-Joao","family":"Santiago-Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7087-2312","authenticated-orcid":false,"given":"Nicolas","family":"Arlicot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,20]]},"reference":[{"key":"1152_CR1","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1113\/jphysiol.1960.sp006410","volume":"150","author":"DR Curtis","year":"1960","unstructured":"Curtis, D. R., Phillis, J. W. & Watkins, J. C. The chemical excitation of spinal neurones by certain acidic amino acids. J. Physiol. 150, 656\u2013682 (1960).","journal-title":"J. Physiol."},{"key":"1152_CR2","first-page":"2","volume":"14","author":"P Jenner","year":"2019","unstructured":"Jenner, P. & Caccia, C. The role of glutamate in the healthy brain and in the pathophysiology of Parkinson\u2019s disease. Eur. Neurol. Rev 14, 2\u201312 (2019).","journal-title":"Eur. Neurol. Rev"},{"key":"1152_CR3","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00702-014-1180-8","volume":"121","author":"Y Zhou","year":"2014","unstructured":"Zhou, Y. & Danbolt, N. C. Glutamate as a neurotransmitter in the healthy brain. J. Neural Transm. 121, 799\u2013817 (2014).","journal-title":"J. Neural Transm."},{"key":"1152_CR4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/pcn.12823","volume":"73","author":"Y Uno","year":"2019","unstructured":"Uno, Y. & Coyle, J. T. Glutamate hypothesis in schizophrenia. Psychiatry Clin. Neurosci. 73, 204\u2013215 (2019).","journal-title":"Psychiatry Clin. Neurosci."},{"key":"1152_CR5","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nrd.2017.16","volume":"16","author":"JW Murrough","year":"2017","unstructured":"Murrough, J. W., Abdallah, C. G. & Mathew, S. J. Targeting glutamate signalling in depression: progress and prospects. Nat. Rev. Drug Discov. 16, 472\u2013486 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1152_CR6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/14728222.2019.1586885","volume":"23","author":"R Celli","year":"2019","unstructured":"Celli, R. et al. Targeting metabotropic glutamate receptors in the treatment of epilepsy: rationale and current status. Expert Opin. Ther. Targets 23, 341\u2013351 (2019).","journal-title":"Expert Opin. Ther. Targets"},{"key":"1152_CR7","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","volume":"3","author":"GF Koob","year":"2016","unstructured":"Koob, G. F. & Volkow, N. D. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry 3, 760\u2013773 (2016).","journal-title":"Lancet Psychiatry"},{"key":"1152_CR8","doi-asserted-by":"publisher","first-page":"13614","DOI":"10.1523\/JNEUROSCI.1204-14.2014","volume":"34","author":"Z Gu","year":"2014","unstructured":"Gu, Z. et al. A\u03b2 selectively impairs mGluR7 modulation of NMDA signaling in basal forebrain cholinergic neurons: implication in Alzheimer\u2019s disease. J. Neurosci. 34, 13614\u201313628 (2014).","journal-title":"J. Neurosci."},{"key":"1152_CR9","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nrn1763","volume":"6","author":"PJ Conn","year":"2005","unstructured":"Conn, P. J., Battaglia, G., Marino, M. J. & Nicoletti, F. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat. Rev. Neurosci. 6, 787\u2013798 (2005).","journal-title":"Nat. Rev. Neurosci."},{"key":"1152_CR10","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1021\/bi200129s","volume":"50","author":"MR Wood","year":"2011","unstructured":"Wood, M. R., Hopkins, C. R., Brogan, J. T., Conn, P. J. & Lindsley, C. W. \u2018Molecular switches\u2019 on mGluR allosteric ligands that modulate modes of pharmacology. Biochemistry 50, 2403\u20132410 (2011).","journal-title":"Biochemistry"},{"key":"1152_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0304-3940(93)90227-C","volume":"163","author":"R Shigemoto","year":"1993","unstructured":"Shigemoto, R. et al. Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci. Lett. 163, 53\u201357 (1993).","journal-title":"Neurosci. Lett."},{"key":"1152_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00441-006-0266-5","volume":"326","author":"F Ferraguti","year":"2006","unstructured":"Ferraguti, F. & Shigemoto, R. Metabotropic glutamate receptors. Cell Tissue Res. 326, 483\u2013504 (2006).","journal-title":"Cell Tissue Res."},{"key":"1152_CR13","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.neubiorev.2012.12.005","volume":"37","author":"N Matosin","year":"2013","unstructured":"Matosin, N. & Newell, K. A. Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia. Neurosci. Biobehav. Rev. 37, 256\u2013268 (2013).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"1152_CR14","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.bbr.2009.03.039","volume":"202","author":"V Kumaresan","year":"2009","unstructured":"Kumaresan, V. et al. Metabotropic glutamate receptor 5 (mGluR5) antagonists attenuate cocaine priming- and cue-induced reinstatement of cocaine seeking. Behav. Brain Res. 202, 238\u2013244 (2009).","journal-title":"Behav. Brain Res."},{"key":"1152_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fnins.2015.00086","volume":"9","author":"S Terbeck","year":"2015","unstructured":"Terbeck, S., Akkus, F., Chesterman, L. P. & Hasler, G. The role of metabotropic glutamate receptor 5 in the pathogenesis of mood disorders and addiction: combining preclinical evidence with human Positron Emission Tomography (PET) studies. Front. Neurosci. 9, 86 (2015).","journal-title":"Front. Neurosci."},{"key":"1152_CR16","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1113\/jphysiol.2008.150722","volume":"586","author":"G D\u00f6len","year":"2008","unstructured":"D\u00f6len, G. & Bear, M. F. Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome. J. Physiol. 586, 1503\u20131508 (2008).","journal-title":"J. Physiol."},{"key":"1152_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026077","volume":"6","author":"MV Mehta","year":"2011","unstructured":"Mehta, M. V., Gandal, M. J. & Siegel, S. J. mGluR5-antagonist mediated reversal of elevated stereotyped, repetitive behaviors in the VPA model of autism. PLoS ONE 6, e26077 (2011).","journal-title":"PLoS ONE"},{"key":"1152_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd2760","volume":"8","author":"PJ Conn","year":"2009","unstructured":"Conn, P. J., Christopoulos, A. & Lindsley, C. W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov. 8, 41\u201354 (2009).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1152_CR19","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/nrd746","volume":"1","author":"A Christopoulos","year":"2002","unstructured":"Christopoulos, A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev. Drug Discov. 1, 198\u2013210 (2002).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1152_CR20","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.molmed.2010.08.005","volume":"16","author":"J Levenga","year":"2010","unstructured":"Levenga, J., de Vrij, F. M. S., Oostra, B. A. & Willemsen, R. Potential therapeutic interventions for fragile X syndrome. Trends Mol. Med. 16, 516\u2013527 (2010).","journal-title":"Trends Mol. Med."},{"key":"1152_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-34978-4","volume":"8","author":"R Hagerman","year":"2018","unstructured":"Hagerman, R. et al. Mavoglurant in Fragile X Syndrome: results of two open-label, extension trials in adults and adolescents. Sci. Rep. 8, 16970 (2018).","journal-title":"Sci. Rep."},{"key":"1152_CR22","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1176\/appi.ajp.2011.09111607","volume":"168","author":"A Deschwanden","year":"2011","unstructured":"Deschwanden, A. et al. Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study. Am. J. Psychiatry 168, 727\u2013734 (2011).","journal-title":"Am. J. Psychiatry"},{"key":"1152_CR23","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1002\/med.21566","volume":"39","author":"Y Xu","year":"2019","unstructured":"Xu, Y. & Li, Z. Imaging metabotropic glutamate receptor system: application of positron emission tomography technology in drug development. Med. Res. Rev. 39, 1892\u20131922 (2019).","journal-title":"Med. Res. Rev."},{"key":"1152_CR24","first-page":"698","volume":"47","author":"SM Ametamey","year":"2006","unstructured":"Ametamey, S. M. et al. Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. J. Nucl. Med. 47, 698\u2013705 (2006).","journal-title":"J. Nucl. Med."},{"key":"1152_CR25","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/syn.20445","volume":"61","author":"J-Q Wang","year":"2007","unstructured":"Wang, J.-Q., Tueckmantel, W., Zhu, A., Pellegrino, D. & Brownell, A.-L. Synthesis and preliminary biological evaluation of 3-[18F]fluoro-5-(2-pyridinylethynyl)benzonitrile as a PET radiotracer for imaging metabotropic glutamate receptor subtype 5. Synapse 61, 951\u2013961 (2007).","journal-title":"Synapse"},{"key":"1152_CR26","doi-asserted-by":"publisher","first-page":"388","DOI":"10.2967\/jnumed.112.107995","volume":"54","author":"DF Wong","year":"2013","unstructured":"Wong, D. F. et al. 18F-FPEB, a PET radiopharmaceutical for quantifying metabotropic glutamate 5 receptors: a first-in-human study of radiochemical safety, biokinetics, and radiation dosimetry. J. Nucl. Med. 54, 388\u2013396 (2013).","journal-title":"J. Nucl. Med."},{"key":"1152_CR27","doi-asserted-by":"publisher","unstructured":"Kang, Y. et al. 18F-FPEB PET\/CT shows mGluR5 upregulation in Parkinson\u2019s disease. J Neuroimaging https:\/\/doi.org\/10.1111\/jon.12563. (2018).","DOI":"10.1111\/jon.12563"},{"key":"1152_CR28","first-page":"449","volume":"2","author":"CG Abdallah","year":"2017","unstructured":"Abdallah, C. G. et al. Metabotropic glutamate receptor 5 and glutamate involvement in major depressive disorder: a multimodal imaging study. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 2, 449\u2013456 (2017).","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging"},{"key":"1152_CR29","doi-asserted-by":"publisher","first-page":"682","DOI":"10.2967\/jnumed.117.199422","volume":"59","author":"G Leurquin-Sterk","year":"2018","unstructured":"Leurquin-Sterk, G. et al. Lower limbic metabotropic glutamate receptor 5 availability in alcohol dependence. J. Nucl. Med. 59, 682\u2013690 (2018).","journal-title":"J. Nucl. Med."},{"key":"1152_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40673-018-0082-1","volume":"5","author":"SH Fatemi","year":"2018","unstructured":"Fatemi, S. H. et al. Metabotropic glutamate receptor 5 tracer [18F]-FPEB displays increased binding potential in postcentral gyrus and cerebellum of male individuals with autism: a pilot PET study. Cerebellum Ataxias 5, 3 (2018).","journal-title":"Cerebellum Ataxias"},{"key":"1152_CR31","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3389\/fendo.2018.00340","volume":"9","author":"D Chi-Casta\u00f1eda","year":"2018","unstructured":"Chi-Casta\u00f1eda, D. & Ortega, A. Circadian regulation of glutamate transporters. Front. Endocrinol. 9, 340 (2018).","journal-title":"Front. Endocrinol."},{"key":"1152_CR32","doi-asserted-by":"publisher","first-page":"9134","DOI":"10.1523\/JNEUROSCI.22-20-09134.2002","volume":"22","author":"DA Baker","year":"2002","unstructured":"Baker, D. A., Xi, Z.-X., Shen, H., Swanson, C. J. & Kalivas, P. W. The origin and neuronal function of in vivo nonsynaptic glutamate. J. Neurosci. 22, 9134\u20139141 (2002).","journal-title":"J. Neurosci."},{"key":"1152_CR33","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1097\/00000542-199704000-00021","volume":"86","author":"BA Orser","year":"1997","unstructured":"Orser, B. A., Pennefather, P. S. & MacDonald, J. F. Multiple mechanisms of ketamine blockade of N-methyl-d-aspartate receptors. Anesthesiology 86, 903\u2013917 (1997).","journal-title":"Anesthesiology"},{"key":"1152_CR34","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","volume":"17","author":"B Moghaddam","year":"1997","unstructured":"Moghaddam, B., Adams, B., Verma, A. & Daly, D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17, 2921\u20132927 (1997).","journal-title":"J. Neurosci."},{"key":"1152_CR35","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nature03180","volume":"433","author":"JD Rothstein","year":"2005","unstructured":"Rothstein, J. D. et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433, 73\u201377 (2005).","journal-title":"Nature"},{"key":"1152_CR36","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1007\/s00213-015-3868-3","volume":"232","author":"PSS Rao","year":"2015","unstructured":"Rao, P. S. S., Saternos, H., Goodwani, S. & Sari, Y. Effects of ceftriaxone on GLT1 isoforms, xCT and associated signaling pathways in P rats exposed to ethanol. Psychopharmacology 232, 2333\u20132342 (2015).","journal-title":"Psychopharmacology"},{"key":"1152_CR37","doi-asserted-by":"publisher","first-page":"153601211878863","DOI":"10.1177\/1536012118788636","volume":"17","author":"L Kosten","year":"2018","unstructured":"Kosten, L., Verhaeghe, J., Wyffels, L., Stroobants, S. & Staelens, S. Acute ketamine infusion in rat does not affect in vivo [11C]ABP688 binding to metabotropic glutamate receptor subtype 5. Mol. Imaging 17, 1536012118788636 (2018).","journal-title":"Mol. Imaging"},{"key":"1152_CR38","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1038\/jcbfm.2015.35","volume":"35","author":"ER Zimmer","year":"2015","unstructured":"Zimmer, E. R. et al. Imaging in vivo glutamate fluctuations with [(11)C]ABP688: a GLT-1 challenge with ceftriaxone. J. Cereb. Blood Flow. Metab. 35, 1169\u20131174 (2015).","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"1152_CR39","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.2967\/jnumed.113.121608","volume":"54","author":"T Wyckhuys","year":"2013","unstructured":"Wyckhuys, T. et al. N-acetylcysteine- and MK-801-induced changes in glutamate levels do not affect in vivo binding of metabotropic glutamate 5 receptor radioligand 11C-ABP688 in rat brain. J. Nucl. Med. 54, 1954\u20131961 (2013).","journal-title":"J. Nucl. Med."},{"key":"1152_CR40","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/syn.21656","volume":"67","author":"CM Sandiego","year":"2013","unstructured":"Sandiego, C. M. et al. Studies of the metabotropic glutamate receptor 5 radioligand [11 C]ABP688 with N -acetylcysteine challenge in rhesus monkeys: ABP688 and NAC in monkeys. Synapse 67, 489\u2013501 (2013).","journal-title":"Synapse"},{"key":"1152_CR41","doi-asserted-by":"publisher","unstructured":"Holmes, S. E. et al. Measuring the effects of ketamine on mGluR5 using [18F]FPEB and PET. J. Cereb. Blood Flow Metab. https:\/\/doi.org\/10.1177\/0271678X19886316. (2019).","DOI":"10.1177\/0271678X19886316"},{"key":"1152_CR42","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.biopsych.2010.12.023","volume":"69","author":"N Miyake","year":"2011","unstructured":"Miyake, N. et al. Imaging changes in glutamate transmission in vivo with the metabotropic glutamate receptor 5 tracer [11C] ABP688 and N-acetylcysteine challenge. Biol. Psychiatry 69, 822\u2013824 (2011).","journal-title":"Biol. Psychiatry"},{"key":"1152_CR43","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00259-011-2021-8","volume":"39","author":"V Camus","year":"2012","unstructured":"Camus, V. et al. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur. J. Nucl. Med. Mol. Imaging 39, 621\u2013631 (2012).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1152_CR44","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s002590050211","volume":"25","author":"SP Hume","year":"1998","unstructured":"Hume, S. P., Gunn, R. N. & Jones, T. Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals. Eur. J. Nucl. Med. Mol. Imaging 25, 173\u2013176 (1998).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1152_CR45","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.nucmedbio.2013.09.007","volume":"41","author":"S S\u00e9rri\u00e8re","year":"2014","unstructured":"S\u00e9rri\u00e8re, S. et al. In vivo PET quantification of the dopamine transporter in rat brain with [18F]LBT-999. Nucl. Med. Biol. 41, 106\u2013113 (2014).","journal-title":"Nucl. Med. Biol."},{"key":"1152_CR46","doi-asserted-by":"publisher","first-page":"202","DOI":"10.4236\/ojmp.2014.33022","volume":"3","author":"D Arsenault","year":"2014","unstructured":"Arsenault, D. et al. Hypo-anxious phenotype of adolescent offspring prenatally exposed to LPS is associated with reduced mGluR5 expression in hippocampus. Open J. Med. Psychol. 3, 202\u2013211 (2014).","journal-title":"Open J. Med. Psychol."},{"key":"1152_CR47","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/hbm.10123","volume":"19","author":"A Hammers","year":"2003","unstructured":"Hammers, A. et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum. Brain Mapp. 19, 224\u2013247 (2003).","journal-title":"Hum. Brain Mapp."},{"key":"1152_CR48","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1007\/s00259-015-3094-6","volume":"42","author":"E Park","year":"2015","unstructured":"Park, E. et al. Test-retest reproducibility of the metabotropic glutamate receptor 5 ligand [18F]FPEB with bolus plus constant infusion in humans. Eur. J. Nucl. Med. Mol. Imaging 42, 1530\u20131541 (2015).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1152_CR49","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/npp.2011.180","volume":"37","author":"RJ Maddock","year":"2012","unstructured":"Maddock, R. J. & Buonocore, M. H. Comment regarding increased striatal glutamate in schizophrenia. Neuropsychopharmacology 37, 1067\u20131068 (2012).","journal-title":"Neuropsychopharmacology"},{"key":"1152_CR50","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1089\/ars.2011.4391","volume":"18","author":"J Lewerenz","year":"2013","unstructured":"Lewerenz, J. et al. The cystine\/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid. Redox Signal. 18, 522\u2013555 (2013).","journal-title":"Antioxid. Redox Signal."},{"key":"1152_CR51","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1196\/annals.1300.023","volume":"1003","author":"DA Baker","year":"2003","unstructured":"Baker, D. A. et al. N-acetyl cysteine-induced blockade of cocaine-induced reinstatement. Ann. N. Y. Acad. Sci. 1003, 349\u2013351 (2003).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1152_CR52","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.neuroimage.2018.10.017","volume":"184","author":"R O\u2019Gorman Tuura","year":"2019","unstructured":"O\u2019Gorman Tuura, R. et al. Imaging glutamate redistribution after acute N-acetylcysteine administration: a simultaneous PET\/MR study. Neuroimage 184, 826\u2013833 (2019).","journal-title":"Neuroimage"},{"key":"1152_CR53","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/jnc.13001","volume":"133","author":"A M\u00fcller Herde","year":"2015","unstructured":"M\u00fcller Herde, A. et al. Quantitative positron emission tomography of mGluR5 in rat brain with [(18) F]PSS232 at minimal invasiveness and reduced model complexity. J. Neurochem. 133, 330\u2013342 (2015).","journal-title":"J. Neurochem."},{"key":"1152_CR54","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3390\/ph11030083","volume":"11","author":"A M\u00fcller Herde","year":"2018","unstructured":"M\u00fcller Herde, A. et al. Ketamine and ceftriaxone-induced alterations in glutamate levels do not impact the specific binding of metabotropic glutamate receptor subtype 5 radioligand [18F]PSS232 in the rat brain. Pharmaceuticals 11, 83 (2018).","journal-title":"Pharmaceuticals"},{"key":"1152_CR55","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/mp.2017.58","volume":"23","author":"I Esterlis","year":"2018","unstructured":"Esterlis, I. et al. Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression. Mol. Psychiatry 23, 824\u2013832 (2018).","journal-title":"Mol. Psychiatry"},{"key":"1152_CR56","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.biopsych.2014.06.024","volume":"77","author":"C DeLorenzo","year":"2015","unstructured":"DeLorenzo, C. et al. In vivo ketamine-induced changes in [11C]ABP688 binding to metabotropic glutamate receptor subtype 5. Biol. Psychiatry 77, 266\u2013275 (2015).","journal-title":"Biol. Psychiatry"},{"key":"1152_CR57","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1007\/s11064-010-0154-y","volume":"35","author":"CA Castillo","year":"2010","unstructured":"Castillo, C. A. et al. Glutamate differently modulates metabotropic glutamate receptors in neuronal and glial cells. Neurochem. Res. 35, 1050\u20131063 (2010).","journal-title":"Neurochem. Res."},{"key":"1152_CR58","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2967\/jnumed.119.228825","volume":"61","author":"J Ceccarini","year":"2020","unstructured":"Ceccarini, J. et al. Recovery of decreased metabotropic glutamate receptor 5 availability in abstinent alcohol-dependent patients. J. Nucl. Med. 61, 256\u2013262 (2020).","journal-title":"J. Nucl. Med."}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-020-01152-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-020-01152-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-020-01152-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T15:20:04Z","timestamp":1669821604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-020-01152-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,20]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["1152"],"URL":"https:\/\/doi.org\/10.1038\/s41398-020-01152-2","relation":{},"ISSN":["2158-3188"],"issn-type":[{"type":"electronic","value":"2158-3188"}],"subject":[],"published":{"date-parts":[[2021,1,20]]},"assertion":[{"value":"23 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"66"}}